NASDAQ:KROS Keros Therapeutics (KROS) Stock Price, News & Analysis $10.73 -0.42 (-3.77%) As of 01:06 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Keros Therapeutics Stock (NASDAQ:KROS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Keros Therapeutics alerts:Sign Up Key Stats Today's Range$10.70▼$11.1850-Day Range$9.93▼$12.0352-Week Range$9.69▼$22.55Volume59,824 shsAverage Volume345,883 shsMarket Capitalization$212.78 millionP/E RatioN/ADividend YieldN/APrice Target$20.50Consensus RatingHold Company Overview Keros Therapeutics, Inc. (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need. The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis. KER-050 is currently being evaluated in multiple clinical trials across North America and Europe. In parallel, Keros is advancing additional preclinical programs that leverage its proprietary platform to address other hematologic and iron-related disorders. Founded in 2019 as a spin-out from academic research, Keros Therapeutics is headquartered in Boston, Massachusetts, and collaborates with leading research institutions and clinical centers worldwide. The company’s leadership team comprises industry veterans in research and development, clinical operations and regulatory affairs, all focused on translating groundbreaking science into therapies that improve patient outcomes in serious blood diseases.AI Generated. May Contain Errors. Read More Keros Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreKROS MarketRank™: Keros Therapeutics scored higher than 61% of companies evaluated by MarketBeat, and ranked 333rd out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingHold Consensus RatingKeros Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.22, and is based on no strong buy ratings, 4 buy ratings, 3 hold ratings, and 2 sell ratings.Upside PotentialKeros Therapeutics has a consensus price target of $20.50, representing about 89.7% upside from its current price of $10.81.Amount of Analyst CoverageKeros Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Keros Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Keros Therapeutics are expected to decrease in the coming year, from ($5.12) to ($6.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Keros Therapeutics is -2.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Keros Therapeutics is -2.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKeros Therapeutics has a P/B Ratio of 0.70. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.12% of the float of Keros Therapeutics has been sold short.Short Interest Ratio / Days to CoverKeros Therapeutics has a short interest ratio ("days to cover") of 4.08.Change versus previous monthShort interest in Keros Therapeutics has recently increased by 3.17%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKeros Therapeutics does not currently pay a dividend.Dividend GrowthKeros Therapeutics does not have a long track record of dividend growth. News and Social Media2.4 / 5News Sentiment-0.11 News SentimentKeros Therapeutics has a news sentiment score of -0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 21 news articles for Keros Therapeutics this week, compared to 3 articles on an average week.Search Interest1 people have searched for KROS on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Keros Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership2.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Keros Therapeutics insiders have sold 783.16% more of their company's stock than they have bought. Specifically, they have bought $10,190.00 in company stock and sold $89,994.00 in company stock.Percentage Held by Insiders12.60% of the stock of Keros Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions71.56% of the stock of Keros Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Keros Therapeutics' insider trading history. Receive KROS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Keros Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KROS Stock News HeadlinesKeros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Recommendation of "Hold" from BrokeragesAugust 10 at 2:15 AM | americanbankingnews.comKeros Therapeutics (NASDAQ:KROS) Rating Increased to Sell at Wall Street ZenAugust 8 at 2:32 AM | americanbankingnews.comTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 is orchestrating what analyst Porter Stansberry calls a total U.S. money reset, bypassing conventional legal channels under the guise of national security. The last time America reset its currency - under Nixon in the 1970s - it created an average of 1,300 new millionaires a day for over 50 years. Stansberry has identified three asset categories connected to Trump's initiative that could surge, plus his single top investment move.August 10 at 1:00 AM | Porter & Company (Ad)Equities Analysts Offer Predictions for KROS FY2026 EarningsAugust 8 at 1:44 AM | americanbankingnews.comWells Fargo Issues a Buy Rating on Keros Therapeutics (KROS)August 6, 2026 | theglobeandmail.comLeerink Partners Lowers Keros Therapeutics (NASDAQ:KROS) Price Target to $23.00August 6, 2026 | americanbankingnews.comAnalysts Are Bullish on Top Healthcare Stocks: Ocular Therapeutix (OCUL), Keros Therapeutics (KROS)August 5, 2026 | theglobeandmail.comKeros Therapeutics Reports Second Quarter 2026 Financial ResultsAugust 3, 2026 | globenewswire.comSee More Headlines KROS Stock Analysis - Frequently Asked Questions How have KROS shares performed this year? Keros Therapeutics' stock was trading at $20.36 on January 1st, 2026. Since then, KROS stock has decreased by 46.9% and is now trading at $10.8050. How were Keros Therapeutics' earnings last quarter? Keros Therapeutics, Inc. (NASDAQ:KROS) posted its earnings results on Monday, August, 3rd. The company reported ($1.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.34) by $0.11. Keros Therapeutics had a negative net margin of 256.60% and a negative trailing twelve-month return on equity of 21.40%. When did Keros Therapeutics IPO? Keros Therapeutics (KROS) raised $90 million in an initial public offering (IPO) on Wednesday, April 8th 2020. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, SVB Leerink and Piper Sandler served as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager. Who are Keros Therapeutics' major shareholders? Top institutional investors of Keros Therapeutics include BlackRock Inc. (14.09%), Bank of New York Mellon Corp (0.52%) and Deutsche Bank AG (0.24%). Insiders that own company stock include Carl L Gordon, Carl L Gordon, Jean Jacques Bienaime, Charles W Newton, Julius Knowles, Nima Farzan, Alpna Seth, Pontifax Management 4 GP (20 and Adar1 Capital Management, Llc. View institutional ownership trends. How do I buy shares of Keros Therapeutics? Shares of KROS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Keros Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Keros Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Meta Platforms (META) and Home Depot (HD). Company Calendar Last Earnings8/03/2026Today8/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (5m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 KROS's financial health is in the Red zone, according to TradeSmith. KROS has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:KROS CIK1664710 Webwww.kerostx.com Phone617-314-6297FaxN/AEmployees100Year Founded2015Price Target and Rating Average Price Target for Keros Therapeutics$20.50 High Price Target$27.00 Low Price Target$16.00 Potential Upside/Downside+91.1%Consensus RatingHold Rating Score (0-4)2.22 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($3.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$87.01 million Net Margins-256.60% Pretax Margin-573.45% Return on Equity-21.40% Return on Assets-19.79% Debt Debt-to-Equity RatioN/A Current Ratio21.96 Quick Ratio21.96 Sales & Book Value Annual Sales$244.06 million Price / Sales0.87 Cash Flow$4.36 per share Price / Cash Flow2.46 Book Value$15.51 per share Price / Book0.69Miscellaneous Outstanding Shares19,830,000Free Float17,329,000Market Cap$212.78 million OptionableOptionable Beta0.99 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:KROS) was last updated on 8/10/2026 by MarketBeat.com Staff. From Our PartnersHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredFDA Clears This Under-$5 Biotech for Phase 2 Clinical TrialA NASDAQ-listed biotech just cleared a major FDA milestone. Its lead therapy, Lucid-MS, has been cleared for P...The Tomorrow Investor | SponsoredSpaceX is NOT the #1 IPO of 2026A lesser known AI company is growing faster than both SpaceX and OpenAI. Its coding business reportedly grew f...The Oxford Club | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThis Junior Silver Explorer Is Closing In on Its Biggest CatalystA past-producing Nevada silver project holds a historical 36 million ounce silver-equivalent resource, plus mo...Wall Street Logic | SponsoredBarricks gold output fell from 2 million ounces to 719000Barrick's gold production has plunged from 2 million ounces to just 719,000, leaving the world's second-larges...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keros Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
